HolderBook

Spruce Street Capital LP

Reported holdings as of Q2 2026, from 3 quarterly filings.

CIK
2050194
Reported value
$509.7M
Positions
30
Top 10 weight
70.2%
Filed
2026-08-13
Days after quarter end
44

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
KINIKSA PHARMACEUTICALS INTLKNSA$58.7M918,07011.52%+2.71pp3q+20.6%+$10.0M
RELAY THERAPEUTICS INCRLAY$55.8M2,984,12510.95%+3.82pp3qHELD
LB PHARMACEUTICALS INCLBRX$44.7M1,376,1598.76%+0.67pp3qHELD
RELMADA THERAPEUTICS INCRLMD$44.2M6,391,3288.68%-1.66pp3q+2.1%+$894.2K
ALTO NEUROSCIENCE INCANRO$35.7M1,353,0477.01%+0.01pp3q+2.1%+$734.6K
DIANTHUS THERAPEUTICS INCDNTH$34.6M354,8166.79%-0.75pp3q-4.9%-$1.8M
ALKERMES PLCALKS$28.5M543,8765.59%+2.89pp2q+71.0%+$11.8M
SAVARA INCSVRA$21.3M3,452,5764.17%-0.27pp3q+2.1%+$427.5K
VAXCYTE INCPCVX$17.8M306,0473.49%+0.06pp3q+24.6%+$3.5M
ENLIVEN THERAPEUTICS INCELVN$16.7M329,0063.28%+0.18pp3qHELD
ENANTA PHARMACEUTICALS INCENTA$15.9M1,088,7313.11%+0.28pp3q+16.7%+$2.3M
PERSPECTIVE THERAPEUTICS INCCATX$12.6M3,693,9312.47%-0.16pp2q+40.6%+$3.6M
INFLARX NVIFRX$12.0M5,352,1982.35%-newNEW
SURROZEN INCSRZN$11.2M432,0402.20%-0.83pp3qHELD
ALUMIS INCALMS$11.0M392,5742.17%+0.09pp2qHELD
CENTURY THERAPEUTICS INCIPSC$9.9M4,059,0541.95%-0.25pp3qHELD
MINERVA NEUROSCIENCES INCNERV$9.2M1,655,5001.80%-0.60pp3qHELD
SAB BIOTHERAPEUTICS INCSABS$8.6M2,198,5021.68%-0.34pp3qHELD
AN2 THERAPEUTICS INCANTX$8.0M1,661,0731.58%+0.24pp2qHELD
ERASCA INCERAS$7.7M422,5431.52%-0.12pp3qHELD
INHIBIKASE THERAPEUTICS INCIKT$7.3M3,581,6031.43%-0.02pp3qHELD
RESEARCH ALLIANCE CORP IIIRACC$5.3M500,0001.05%-newNEW
HELIX ACQUISITION CORP IIIHLXC$5.3M500,0001.04%-0.18pp2qHELD
ZAI LAB LTDZLAB$5.3M279,1101.04%-newNEW
ACHIEVE LIFE SCIENCE INCACHV$4.8M736,6370.94%-newNEW
LEXEO THERAPEUTICS INCLXEO$4.3M928,5930.85%-0.43pp3qHELD
ALECTOR INCALEC$4.2M2,101,0680.83%-0.26pp3qHELD
LEONABIO INCLONA$3.6M393,7010.71%-0.21pp3qHELD
CORVUS PHARMACEUTICALS INCCRVS$3.5M231,5850.68%-0.14pp2qHELD
JATT II ACQUISITION CORP$1.8M160,0000.36%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 97.5%Other sectors 1.0%Not classified 1.4%
 
SectorValueShare
Biotech & Pharma$497.2M97.5%
Other sectors$5.3M1.0%
Not classified$7.2M1.4%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$509.7M30581370.2%44
Q1 2026$415.9M287123665.8%44
Q4 2025$302.7M27000070.8%44

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.